Anastrozole + Tamoxifen
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bone Density
Conditions
Bone Density
Trial Timeline
Jun 1, 1998 → Apr 1, 2007
NCT ID
NCT00784940About Anastrozole + Tamoxifen
Anastrozole + Tamoxifen is a phase 3 stage product being developed by AstraZeneca for Bone Density. The current trial status is completed. This product is registered under clinical trial identifier NCT00784940. Target conditions include Bone Density.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00537771 | Approved | Completed |
| NCT00784940 | Phase 3 | Completed |
| NCT00784862 | Phase 3 | Completed |
| NCT00784680 | Phase 3 | Completed |
| NCT00286117 | Phase 3 | Completed |
| NCT00287534 | Phase 2 | Completed |
Competing Products
20 competing products in Bone Density
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 77 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Merestinib | Eli Lilly | Phase 1 | 33 |
| FORTEO + Placebo | Eli Lilly | Phase 1 | 33 |
| Arzoxifene + Placebo | Eli Lilly | Phase 3 | 77 |
| Tanezumab | Eli Lilly | Phase 3 | 77 |
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic acid + Letrozole | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 1 | 33 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 85 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 77 |
| zoledronic acid | Novartis | Phase 1 | 33 |
| Ruxolitinib continuous therapy | Novartis | Phase 2 | 52 |
| zoledronic acid | Novartis | Approved | 85 |